Results of a non-interventional real-world evaluation (EZRA): a fixed combination of rosuvastatin and ezetimibe in patients with primary hypercholesterolemia
Authors:
Eva Tůmová 1; Jana Mašková 2; Jiří Laštůvka 3; Michal Vrablík 1
Authors‘ workplace:
III. interní klinika, klinika endokrinologie a metabolismu, 1. LF UK a VFN v Praze
1; EMMES BIOPHARMA GLOBAL s. r. o.
2; Interní oddělení, Masarykova nemocnice v Ústí nad Labem, o. z, Krajská zdravotní, a. s
3
Published in:
AtheroRev 2022; 7(1): 35-41
Category:
Clinical Studies
Overview
We reduce cardiovascular risk through a comprehensive intervention of modifiable risk factors. Among them, the treatment of dyslipidemia dominates, when achieving the target values of atherogenic lipids significantly improves the prognosis of patients. The cross-sectional monitoring of EZRA evaluated the achievement of treatment goals in the field of dyslipidemia in a cohort of patients with an average to very high cardiovascular risk monitored by outpatient specialists in conditions of routine practice. Patients indicated for the combination of rosuvastatin and ezetimibe were enrolled and the effect of including a fixed combination of these drugs on dyslipidemia control was evaluated. After 3 months of follow-up, an average decrease in LDL-C of 32 % was achieved, triglyceridemia decreased by 22 %. The number of patients reaching the target values in the very high risk category increased fivefold, and even tenfold in the high risk category. EZRA monitoring recalls the importance of hypolipidemic combination therapy, which should be offered to virtually all patients at high and very high CV risk, preferably in a fixed combination.
Keywords:
fixed combination – cardiovascular risk – ezetimibe – rosuvastatin – LDL-cholesterol
Sources
1. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10(4): S1-S10. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjr.0000087913.96265.e2>.
2. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: Fourth Joint Task Force of European Society of Cardiology and other societies. Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl 2): S1–113. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjr.0000277983.23934.c9>.
3. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk. A review for clinicians. J Am Coll Cardiol 2009; 54(14):1209–1227. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2009.07.020>.
4. Cooney MT, Dudina A, d’Agostino R et al. Cardiovascular risk estimation systems in primary prevention. Do they differ? Do they make difference? Can we see the future? Circulation 2010;122(3): 300–310. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.852756>.
5. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11): 987– 1003. Dostupné z DOI: <http://dx.doi.org/10.1016/s0195–668x(03)00114–3>.
6. Mach F, Baigent C, Catapano AL et al. [ESC Scientific Document Group]. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019; pii: ehz455. Dostupné z DOI:<http://dx.doi.org/10.1093/eurheartj/ehz455>
7. Catapano AL, Reiner Z, De Backer G et al. Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217(Suppl 1): S1–S44. Dostupné z DOI: <https://doi.org/10.1016/j.atherosclerosis.2011.06.012>.
8. Vrablík M, Piťha J, Bláha V et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. Vnitr Lek 2019; 65(12): 743–754. Dostupné z DOI: <http://dx.doi.org/10.36290/vnl.2019.131>.
9. Vrablík M. Kombinace statin a ezetimib: častěji v jedné tabletě a pro více pacientů. AtheroRev 2021; 6(3): 133–137.
10. Vrablík M, Seifert B, Pakhomenko A et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis 2021. Přijato k publikaci 8/2021.
11. Šatný M, Mašková J, Laštůvka J et al. Profil pacientů s nekontrolovanou arteriální hypertenzí a/nebo dyslipidemií v primární péči v Česku – studie LipitenCliDec: výsledky 1. fáze. AtheroRev 2020; 5(1): 47–52.
12. Mayer O, Bruthans J, Rychecká M. Změny úrovně sekundární prevence ischemické choroby srdeční mezi lety 1995–2017 v České republice: porovnání studií EUROASPIRE I, II, III, IV a V. Vnitr Lek 2018; 64(12): 1190–1199.
13. Cífková R, Bruthans J, Wohlfahrt P et al. 30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post- MONICA, 1985–2016/17. PLoS One 2020; 15(5): e0232845. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0232845>.
14. Baigent C, Blackwell L, Emberson J et al. [Cholesterol Treatment Trialists’ (CTT) Collaboration]. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61350–5.
15. Masuda D, Nakagawa-Toyama Y, Nakatani K et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009; 39(8): 689–698. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2362.2009.02163.x>.
16. Davidson MH. Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. J Am Coll Cardiol 2003; 42(2): 398–399; author reply 399. Dostupné z DOI: <http://dx.doi.org/10.1016/s0735–1097(03)00638–7>.
17. Baigent C, Blackwell L, Emberson J et al. [Cholesterol Treatment Trialists’ (CTT) Collaboration]. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61350–5>.
18. Augustin A, Coutts L, Zanisi L. Impact of Therapeutic Inertia on Long- -Term Blood Pressure Control: A Monte Carlo Simulation Study. Hypertension 2021; 77(4): 1350–1359. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15866>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2022 Issue 1
Most read in this issue
- Early prevention of cardiovascular events – recent data and practical approach
- Immuno-thrombosis, coagulopathy, pulmonary embolism and diagnosis in patients with COVID-19
- Familial dysbetalipoproteinemia: known unknown
- The effect of mechanical circulatory supports on the vascular system